Lemtrada

As single disease modifying therapy (DMT) in adults w/ highly active relapsing remitting multiple sclerosis (RRMS) for patients w/ highly active disease despite full & adequate course of treatment w/ at least 1 DMT; or w/ rapidly evolving severe RRMS defined by ≥2 disabling relapses in 1 yr & w/ ≥1 gadolinium-enhancing lesions on brain MRI or significant increase in T2 lesion load as compared to previous recent MRI.

IV infusion Adult Recommended dose: 12 mg daily for 2 initial treatment courses. 1st treatment course: 12 mg daily on 5 consecutive days (60 mg total dose). 2nd treatment course: 12 mg daily on 3 consecutive days (36 mg total dose) administered 12 mth after 1st treatment course. May consider up to 2 additional treatment courses if needed: 3rd or 4th course: 12 mg daily on 3 consecutive days (36 mg total dose) administered at least 12 mth after prior treatment course. Pre-treatment: Immediately administer corticosteroids prior to Lemtrada on each of the 1st 3 days of any treatment course. May also consider pretreatment w/ antihistamines &/or antipyretics prior to administration. Administer oral prophylaxis for herpes infection on 1st day of each treatment course & continuing for min of 1 mth following Lemtrada.

Hypersensitivity. HIV infection. Patients w/ severe active infection until complete resolution; uncontrolled HTN; history of arterial dissection of cervicocephalic arteries, stroke, angina pectoris or MI; known coagulopathy, on anti-platelet or anti-coagulant therapy; other concomitant autoimmune diseases (besides multiple sclerosis).

Targeted Cancer Therapy

L04AG06 - alemtuzumab ; Belongs to the class of monoclonal antibodies. Used as immunosuppressants.

POM